
Intuitive Surgical, Inc.

ISRG (Intuitive Surgical, Inc.) trades at 14.6x EV/Revenue — moderately valued for a biotech & healthcare company with strong gross margins (66%) and mature growth profile. The business is highly profitable at 36% EBIT margins. Forward PE of 48x.
The Rule of 72: divide 72 by your annual return to estimate years to double. At 10%, your money doubles every 7.2 years.
Gold Eagle provides data and AI-generated analysis for informational purposes only. Not investment advice. All data from public sources.
Intuitive Surgical develops, manufactures, and markets robotic-assisted surgical systems, primarily the da Vinci platform, which enables minimally invasive surgery through tiny incisions. Their customers are hospitals and surgical centers worldwide, and they generate revenue through system sales, recurring instrument and accessory sales, and service contracts. The company essentially transforms traditional open surgery into precise, minimally invasive procedures controlled by surgeons through a console.
Revenue has grown at a mid-teens CAGR over the past five years, driven by expanding procedure volumes and new system placements. The total addressable market exceeds $100 billion across general surgery, urology, gynecology, and emerging specialties. Growth is fueled by increasing surgeon training, expanding clinical evidence, and geographic expansion into international markets.
Gross margins consistently run in the high 60% range, with the recurring instruments and services business generating margins above 70%. Operating margins have expanded to the mid-30s as the company achieves scale efficiencies. Free cash flow generation is robust, typically converting 25-30% of revenue to cash, enabling significant R&D reinvestment and shareholder returns.
ISRG maintains a strong competitive moat through its large installed base, extensive surgeon training programs, and continuous innovation in instruments and software. While facing new competition, the company benefits from high switching costs and network effects as more surgeons become trained on da Vinci systems. The platform's versatility across multiple surgical specialties provides defensive positioning.
Without access to recent financial data, the company has historically shown consistent procedure growth driven by both existing system utilization and new installations. The stock has generally responded positively to quarterly updates showing sustained procedure volume increases and margin expansion, though valuation concerns occasionally weigh on investor sentiment.
Analysts typically maintain positive long-term views on ISRG given its market-leading position and secular growth trends in minimally invasive surgery. Debate centers on valuation multiples and the pace of competitive threats, with bulls emphasizing the large addressable market and bears concerned about premium pricing sustainability.
ISRG remains the dominant player in robotic surgery with a proven recurring revenue model, though investors must weigh its premium valuation against increasing competitive pressures and the pace of market expansion.








| '25E | '26E | '27E | '28E | |
|---|---|---|---|---|
| Revenue | — | $11.5B | $13.1B | $15.0B |
| Growth | — | +14% | +14% | |
| EBITDA | — | $3.9B | $4.4B | $5.1B |
| Growth | — | +14% | +14% | |
| EPS (PF) | — | $10.05 | $11.48 | $13.22 |
| Growth | — |
| +14% |
| +15% |